Do you routinely obtain serum anti-THSD7A and anti-NELL1 tests in your patients with nephrotic syndrome suspected secondary to membraneous nephropathy?  

I usually follow up on serum anti-THSD7A titers in patients with kidney biopsy-proven THSD7A (+) Membranous Nephropathy. The Serum NELL-1 titer is not yet commercially available and is available only in the research setting that needs further validation.